

SeQuent receives Establishment Inspection Report from US FDA for its API Drug Manufacturing Facility at Mangalore

Mumbai, November 9, 2015: SeQuent Scientific Limited today announced that its API Drug Manufacturing facility at Mangalore, Karnataka (SeQuent Mangalore facility) which was inspected by the USFDA in June 2015 as part of GMP compliance audit has received Establishment Inspection Report (EIR), thereby confirming the closure of the inspection in June 2015.

The previous USFDA inspection for this facility was in the year 2012. The facility continues its status of being acceptable by USFDA

The SeQuent Mangalore facility is ISO 9001 certified for Quality Management systems and ISO 14000 certified for Environment Management systems. This state-of-the-art facility engaged in the development and manufacture of APIs and API Intermediaries. In addition to the USFDA, the site is also approved by TGA (Australia), and WHO (Geneva) and has four CEPs for its APIs (EDQM) with more in pipeline.

SeQuent Mangalore specializes in niche and difficult to manufacture APIs and has 5 of its APIs prequalified by WHO Prequalification of Medicines program. It has filed more than 30 drug master files covering USFDA, Europe, WHO, Australia, Canada with several more niche APIs in the pipeline for future filings.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-SEQUENT/512529) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has seven manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

SeQuent 's Animal Health business is operated through its subsidiary Alivira Animal Health Ltd and SeQuent is poised to emerge as a global powerhouse in animal health business, built on a platform of superior quality and compliance.

For Queries, please contact

Ankit Gupta

Christensen Investor Relations

Tel : +91 22 42150210

ankitgupta@christensenir.com

Registered Office

SeQuent Scientific Limited

CIN: L99999MH1985PLC036685

BSE Code:512529

301/A, 'Dosti Pinnacle',
Plot No.E7,Road No. 22,
Wagle Industrial Area, Thane (W),
Maharashtra, India

ISIN: INE807F01019

REUTERS: SEQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.